BG
Bellevue Group Portfolio holdings
AUM
$4.54B
1-Year Return
22.5%
This Quarter Return
+27.29%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$6.31B
AUM Growth
+$931M
(+17%)
Cap. Flow
-$8.53M
Cap. Flow
% of AUM
-0.14%
Top 10 Holdings %
Top 10 Hldgs %
41.19%
Holding
231
New
21
Increased
88
Reduced
44
Closed
16
Top Buys
| 1 |
Bristol-Myers Squibb
BMY
|
$74M |
| 2 |
Charles River Laboratories
CRL
|
$42M |
| 3 |
Abbott
ABT
|
$19.7M |
| 4 |
MTEM
Molecular Templates, Inc.
MTEM
|
$18.1M |
| 5 |
Arvinas
ARVN
|
$17.9M |
Top Sells
| 1 |
CELG
Celgene Corp
CELG
|
$108M |
| 2 |
BOLD
Audentes Therapeutics, Inc
BOLD
|
$84.8M |
| 3 |
ALDR
Alder Biopharmaceuticals, Inc.
ALDR
|
$84.7M |
| 4 |
Gilead Sciences
GILD
|
$35.3M |
| 5 |
Teladoc Health
TDOC
|
$32.6M |
Sector Composition
| 1 | Healthcare | 95.59% |
| 2 | Industrials | 0.45% |
| 3 | Technology | 0.42% |
| 4 | Communication Services | 0.09% |
| 5 | Financials | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BMY.RT
126
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $2.46M | 0.04% |
+816,600
| New | +$2.46M |
|
127
Pfizer
PFE
$141B
| $2.35M | 0.04% |
63,240
+21,080
| +50% | +$784K |
|
128
Kura Oncology
KURA
$713M
| $2.17M | 0.03% |
157,800
-8,500
| -5% | -$117K |
|
|
MRTX
129
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $2.1M | 0.03% |
16,300
+400
| +3% | +$51.5K |
|
130
uniQure
QURE
$985M
| $2.07M | 0.03% |
28,900
-2,000
| -6% | -$143K |
|
131
Sarepta Therapeutics
SRPT
$1.96B
| $2M | 0.03% |
+15,500
| New | +$2M |
|
|
BNFT
132
DELISTED
Benefitfocus, Inc.
BNFT
| $1.99M | 0.03% |
90,463
| – | – |
|
|
CTLT
133
DELISTED
CATALENT, INC.
CTLT
| $1.93M | 0.03% |
34,300
-3,200
| -9% | -$180K |
|
134
Acadia Pharmaceuticals
ACAD
$4.26B
| $1.71M | 0.03% |
40,000
-50,400
| -56% | -$2.16M |
|
135
FibroGen
FGEN
$48.9M
| $1.65M | 0.03% |
+1,540
| New | +$1.65M |
|
136
Fate Therapeutics
FATE
$116M
| $1.62M | 0.03% |
82,800
+22,700
| +38% | +$444K |
|
|
BPMC
137
DELISTED
Blueprint Medicines
BPMC
| $1.62M | 0.03% |
20,200
+4,400
| +28% | +$352K |
|
138
Ligand Pharmaceuticals
LGND
$3.25B
| $1.62M | 0.03% |
+24,847
| New | +$1.62M |
|
139
Viatris
VTRS
$12.2B
| $1.61M | 0.03% |
80,000
-213,200
| -73% | -$4.29M |
|
|
BLUE
140
DELISTED
bluebird bio
BLUE
| $1.61M | 0.03% |
+1,413
| New | +$1.61M |
|
141
ProShares Ultra NASDAQ Biotechnology
BIB
$57.5M
| $1.54M | 0.02% |
+25,000
| New | +$1.54M |
|
142
Agilent Technologies
A
$36.5B
| $1.54M | 0.02% |
18,000
-11,800
| -40% | -$1.01M |
|
143
Neuronetics
STIM
$214M
| $1.46M | 0.02% |
325,961
| – | – |
|
144
Amneal Pharmaceuticals
AMRX
$3.02B
| $1.45M | 0.02% |
+300,000
| New | +$1.45M |
|
|
ZGNX
145
DELISTED
Zogenix, Inc.
ZGNX
| $1.36M | 0.02% |
26,100
+3,100
| +13% | +$162K |
|
|
XLRN
146
DELISTED
Acceleron Pharma Inc.
XLRN
| $1.28M | 0.02% |
24,200
-1,600
| -6% | -$84.8K |
|
147
Repligen
RGEN
$7.01B
| $1.26M | 0.02% |
+13,600
| New | +$1.26M |
|
|
BHVN
148
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $1.24M | 0.02% |
+22,700
| New | +$1.24M |
|
|
GWPH
149
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $1.17M | 0.02% |
11,200
+747
| +7% | +$78.1K |
|
150
Labcorp
LH
$23.2B
| $935K | 0.01% |
6,432
-55
| -0.8% | -$8K |
|